Myomas of the uterus are the most common benign neoplasms in the female pelvis. In addition to the definitive removal of the uterus (hysterectomy) or uterus-preserving procedures (Myomectomy, MRgFUs, UAO, UAE, USgFUS/USgHIFU), intrauterine ultrasound-guided transcervical radiofrequency ablation (TFA) is another uterus-preserving, mostly in the outpatient setting conducted intervention for myomas. In TFA, radiofrequency energy (RF) is used to cause coagulative necrosis of the tissue to reduce the volume and associated symptoms of uterine leiomyomas.

No comparative studies were identified in the course of the search strategy. The study pool for the evaluation of evidence consisted of three prospective single-arm studies (234 patients), which were published in seven publications. The quality of the evidence regarding efficacy and safety was rated as low or very low for all relevant endpoints.

Inclusion in the Austrian benefit catalogue is currently not recommended. Due to the low quality of the evidence, comparative studies of TFA in symptomatic myomas are necessary in order to make a reliable statement regarding clinical efficacy and safety.